Therapeutic Patterns and Clinical Outcomes in Limited Disease Small Cell Lung Cancer: A Decade of Analysis at a Tertiary Cancer Center

In this study, we investigated the outcomes and factors influencing treatment efficacy in 93 patients with limited disease small cell lung cancer (LD-SCLC), with a median age of 64 years. We focused on the impact of chemotherapy regimens, prophylactic cranial irradiation (PCI), and patient-related v...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-05, Vol.16 (11), p.1953
Main Authors: Ziegler, David Alexander, Cleve, Cecilia Christiane, Ziegler, Sonia, Schirmer, Markus Anton, Fischer, Laura Anna, Bohnenberger, Hanibal, Overbeck, Tobias Raphael, Braulke, Friederike, Hammerstein-Equord, Alexander von, Leu, Martin, Guhlich, Manuel, Dröge, Leif Hendrik, Rieken, Stefan, Rittmeyer, Achim, El Shafie, Rami A
Format: Article
Language:English
Subjects:
Cancer
Cancer therapies
Carboplatin
Care and treatment
Chemotherapy
Cisplatin
Clinical trials
Development and progression
Diseases
Etoposide
Germany
Histology
Lung cancer
Lung cancer, Small cell
Lung diseases
Lymphatic system
Magnetic resonance imaging
Medical prognosis
Metastasis
Patient outcomes
Patients
Radiation therapy
Radiotherapy
Regression analysis
Skull
Small cell lung carcinoma
Statistical analysis
Toxicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study, we investigated the outcomes and factors influencing treatment efficacy in 93 patients with limited disease small cell lung cancer (LD-SCLC), with a median age of 64 years. We focused on the impact of chemotherapy regimens, prophylactic cranial irradiation (PCI), and patient-related variables. The median follow-up for OS was 17.3 months. We observed a statistically significant difference in PFS between LD-SCLC patients treated with cisplatin and etoposide (EP) and those treated with carboplatin and etoposide (CP) (PFS: EP 13.63 months vs. CP 6.54 months, < 0.01). Patients treated with EP had better overall survival (OS) than CP-treated patients (OS: EP 26.9 months vs. CP 16.16 months, < 0.01). Concomitant chemotherapy was associated with improved PFS ( = 0.003) and OS ( = 0.002). Patients receiving PCI showed superior OS ( = 0.05) and a trend towards improved PFS ( = 0.057). Female gender was associated with better OS ( = 0.025). Most patients had an ECOG performance status of 0 (71%). This real-world study underscores the importance of multidisciplinary LD-SCLC management, emphasizing the roles of chemotherapy, radiotherapy, and PCI. These findings inform personalized treatment strategies and emphasize the need for prospective trials to validate these results and optimize LD-SCLC treatment.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16111953